Navigation Links
GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference
Date:8/7/2013

LONDON, Aug. 8, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the 33rd Annual Canaccord Genuity Growth Conference on Wednesday, 14 August, 2013 at 2:00 p.m. ET. The conference will be held at the InterContinential Boston in Boston, MA.

A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section at www.gwpharm.com.

About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and at least two additional programs expected to enter Phase 1 and Phase 2 clinical trials in the next 12 months. For further information, please visit www.gwpharm.com.


'/>"/>
SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
2. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
3. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
4. RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split
5. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
6. HealthEconomics.Com Launches a New Specialty Pharma Newsletter to Worldwide Community of Industry Insiders Within Specialty Pharmaceuticals
7. Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
8. Piedmont Pharmaceuticals Gains FDA Approval of Animal Health Soft Chew Pain Medication
9. North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017
10. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
11. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) ... Monitoring Board (DSMB) for the Company,s Phase 3 ... has completed a second planned safety review and ... without any modifications. The DSMB reviewed available study ... concerns were identified. The DSMB will conduct additional ...
(Date:12/5/2016)... Research and Markets has announced the ... Technologies, Markets and Companies" to their offering. ... , , ... human genome variations, development of sequencing technologies, and their applications. ... companies developing them. Various applications of sequencing are described including ...
(Date:12/4/2016)... San Francisco, CA (PRWEB) , ... December 03, ... ... scientific grants to ground-breaking microbiome studies. A microbiome impact grant award has been ... study the effect of heavy smoking and drinking on the oral microbiome. Grant ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of AxioMed’s ... disc production, company President, Jake Lubinski will be traveling to Switzerland from December ... in Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. ...
Breaking Biology Technology:
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
Breaking Biology News(10 mins):